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Introduction
H
epatitis C virus (HCV) has been given many 
names,  ‘the  silent  epidemic’,  ‘the  silent 
dragon’  and  ‘the  disease  of  the  new  millennium’. 
According to studies carried out by the World Health 
Organization approximately 170 million individuals 
(3% of the world’s population) have been diagnosed 
with HCV (1) (Fig. 1). Chronic hepatitis C (CHC) 
is considered to account for about 70 to 75% of all 
cases of chronic hepatitis and 15-20% of all cases of 
cirrhosis of the liver and hepatocellular carcinoma 
(2). Pegylated interferon (PEG-IFN) is recommended 
as the standard therapy for chronic hepatitis C. More 
recently, PEG-IFN has been recommended for the 
treatment  of  chronic  hepatitis  C  in  a  once-daily 
dosage. Interferon (IFN) -alpha and Ribavirin act 
by immunomodulation and antiviral mechanisms; 
they also have direct toxic effects on the thyroid (3). 
Production  of  antithyroid  antibodies  and  thyroid 
dysfunction  are  the  most  common  autoimmune 
disorders  associated  with  combination  therapy 
(3-8).  Other  extra  hepatic  diseases  related  to  IFN 
therapy in chronic hepatitis C are diabetes mellitus, 
haematological  disease  and  neuropsychiatric 
disturbances.
Antithyroid Autoantibodies in Chronic Hepatitis C 
Patients
Autoantibodies are commonly found in patients 
with  CHC,  even  without  any  treatment  (Table 
1).  These  include  antinuclear  antibodies  (ANA), 
anti  smooth  muscle  antibodies  (ASMA),  liver/
kidney  antibodies,  antimicrosomal  antibodies 
(AMA),  thyroperoxidase  antibodies  (TPO)  and 
antithyroglobulin antibodies (TGA) (5). The overall 
frequency of non-organ-specific antibodies is found 
to  be  significantly  higher  in  anti-HCV  positive 
patients than in normal healthy individuals (4). These 
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Chronic hepatitis C (CHC) is one of the commonest infectious diseases of the liver and may lead to cirrhosis or hepatocellular 
carcinoma. Combination therapy with pegylated interferon (PEG-IFN) and Ribavirin is the treatment of choice for CHC. 
Combination therapy is thought to act by means of antiviral mechanisms and immunomodulation. Thyroid dysfunction 
is the most common autoimmune adverse effect associated with combination therapy; hypothyroidism is more common 
than hyperthyroidism. Antithyroid antibodies and female sex have a predictive value in the development of interferon   
induced thyroid disease (IITD). Patients with CHC should be informed of the possibility of side effects on the thyroid 
gland. Screening for antithyroid antibodies and thyroid function tests should be performed in patients with CHC before 
the commencement of antiviral treatment, and during and after it. This article reviews different aspects of IITD, including 
its pathogenesis, clinical manifestations, association with treatment regimens and treatment response and the outcome of 
thyroid dysfunction.
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already diagnosed as having Graves’ disease, suffered 
from CHC infection and developed IFN-induced 
severe hypothyroidism. Her hyperthyroidism resumed 
after discontinuation of IFN therapy. It is found that 
females carry a higher risk of developing IITD (4, 7, 
22,  24,  30,  31). Although  rare,  IFN-induced  Graves’ 
opthalmopathy has also been reported  (32). Other 
predisposing factors include the presence of thyroid 
autoantibodies  and  Asian  ethnicity  (32).  Vertical 
transmission of HCV infection is well documented 
in  the  literature.  In  a  study,  11.1%  of  untreated 
chronic hepatitis C children infected through vertical 
transmission  revealed  subclinical  hypothyroidism, 
without  any  evidence  of  autoantibodies  (33). In 
addition to clinical manifestations and biochemical 
changes, IITD also leads to thyroid hypoechogenicity 
on  ultrasonography,  which  suggests  relevant 
morphological changes in the thyroid gland as well 
as functional changes (16, 34).
Pathogenesis of IITD
The  exact  mechanisms  in  the  pathogenesis  of 
IITD in patients with HCV infection are not fully 
known,  but  usually  these  disorders  are  reversible 
and  only  require  supervision  and  treatment,  if 
symptomatic. IITD is considered to be caused by 
immunomodulation  and  is  associated  with  the 
production  of  autoantibodies  (9). Autoantibodies 
are not invariably present in all patients developing 
IITD, which suggests that mechanisms other than 
autoimmunity can be involved as well (18). Ribavirin 
also has immunomodulatory effects and acts alone 
or  synergistically  with  IFN-  alpha  to  cause  IITD 
(14).  Ribavirin  is  a  guanosine  analog  and  acts  by 
competitively  inhibiting  inosine  monophosphate 
dehydrogenase,  viral  RNA  polymerase  and  viral 
messenger  RNA  (mRNA)  guanylyltransferase, 
resulting  in  decreased  viral  mRNA  and  protein 
synthesis. Ribavirin is also incorporated into the viral 
genome and causes mutation, resulting in a decrease in 
specific viral infectivity. However, it can also enhance 
non-virus-induced immune responses and can result 
in  autoimmune  diseases  in  genetically  predisposed 
patients  (35).  Ribavirin  has  a  predominantly 
immunological  effect  on  Th1  cytokines  activating 
CD-8+  T  lymphocytes,  which  induce  cellular 
destruction via cellular immunity (35).
The IFNs belong to a group of proteins called 
cytokines which are produced by white blood cells, 
fibroblasts and T lymphocytes as a part of innate 
immunity in response to viral infection. There are 
3  types;  alpha,  beta  and  gamma  IFN.  IFN-alpha 
is used in the treatment of CHC infection. Recent 
data  suggests  that  IFN-alpha  has  direct  toxic 
effects on the thyroid gland, in addition to having 
immunomodulatory mechanisms  (3). The evidence 
of direct toxic effects of IFN on the thyroid is derived 
from  the  findings  of  the  up-regulation  of  TSH 
receptors, increased thyroglobulin, thyroid peroxidase 
enzymes  and  sodium  iodide  symporter  protein 
expression. Moreover, IFN causes induction of heat 
shock proteins and thyroid cell apoptosis (28). IFN 
can also activate natural killer cells, the maturation 
and proliferation of dendritic and memory T cells, 
and the prevention of T cell apoptosis, causing a rise 
in the thyroid autoantibody titer. These antibodies 
will result in thyroid gland damage in genetically 
predisposed individuals (35). Moreover, the human 
leukocyte  antigen-A2  (HLA-A2)  is  also  associated 
with  IFN-alpha  therapy-induced  autoimmune 
thyroid dysfunction in patients with chronic hepatitis 
C (36). In one study, it was found that aggravation 
of fibrosis has no association with the occurrence 
of thyroid autoimmunity and thyroid dysfunction 
(18), whereas another study showed that low fibrosis 
is significantly associated with an increased incidence 
of IITD (17).
It  has  been  suggested  that  only  predisposed 
patients with CHC develop IITD. This predisposition 
may  be  genetic  or  environmental  in  origin.  In 
genetically susceptible individuals, IFN-alpha is one 
of  the  environmental  factors  which  cause  thyroid 
dysfunction  (9).  Although  high  endogenous  IFN-
alpha levels may also be associated with naturally 
occurring autoimmune thyroid disease, HCV itself 
plays a role in the disease because thyroid disease is 
reported in CHC patients even without treatment 
(24).  Moreover,  patients  with  chronic  hepatitis  B 
infection who are treated with higher doses of IFN 
alpha (5 million units as compared to 3 million units 
in CHC) are less likely to develop thyroid disease than 
those with chronic HCV infection (13). This indicates 
that HCV and IFN-alpha may have a synergistic role 
in the pathogenesis of IFN-induced thyroid disease. 
HCV  causes  the  production  of  endogenous  IFN-
alpha and -beta in the thyroid gland as part of innate 
immunity. It is found that HCV envelope protein 
(E2) can bind to CD 81 molecules in thyroid cells, 
inducing IL 8 secretion and activating resident T 
cells  in  genetically  susceptible  individuals  (28).  It 
also suggests that IITD is not associated with dose-
response relationship (13). In various studies, different 
clinical  pictures  of  IFN-induced  thyroid  disease 
occur in CHC patients including hypothyroidism, 
hyperthyroidism or biphasic thyroiditis. Moreover, 
different  manifestations  of  thyroid  disease  can 
occur in the same patient during or after treatment, 
suggesting a possible change in the immunological Hepatitis Monthly, Spring 2010; 10(2): 132-140
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process  induced  by  IFN  treatment  in  genetically 
susceptible  individuals.  Overt  hyperthyroidism 
due  to  subacute  destructive  thyroiditis,  followed 
by Graves’ disease, has been reported in the same 
patient on INF therapy over a short period of ten 
months (29).
The patients who develop Graves, type thyrotoxicosis 
induced by IFN therapy show a different immunological 
response  from  those  showing  hypothyroidism  or 
transient thyrotoxicosis caused by a destructive process 
in the thyroid gland. Type 1 immune response plays a 
critical role in the development of many autoimmune 
diseases and in the resolution of viral infection. In 
thyroid autoimmune diseases, both T helper (Th) 
cells 1 and Th 2 responses coexists in the same patient 
with CHC (37). In Hashimoto’ s thyroiditis and in 
silent  thyroiditis  in  otherwise  normal  individuals 
i.e.  not  suffering  from  CHC,  type  1  immune 
response depicting cellular immunity is enhanced, 
as  demonstrated  by  an  increase  in  serum  Th  1 
cytokines leading to hypothyroidism (37). In Graves’ 
disease, type 2 immune response, depicting humoral 
immunity by the activation of Th cells 2, is associated 
with an increase in thyroid-stimulating autoantibodies 
to thyrotropin receptors (37). It is speculated that the 
same immune mechanisms may be operating in the 
development of different immunologic responses in 
IITD (12). IFN causes intracellular signaling through 
the JAK-STAT pathway, and induces the expression 
of  cytokine  and  adhesion  molecule  genes.  IFN 
increases the expression of the MHC-I antigen on 
thyroid epithelial cells, activating cytotoxic T cells. 
The result is inflammation leading to tissue damage 
(28). Although response to IFN therapy is related to 
both host and viral factors, genetic background seems 
to play a predominant role in determining thyroid 
autoimmunity with IFN (38). Only in those subjects 
genetically predisposed to developing autoimmune 
disease, can combined IFN plus Ribavirin treatment 
trigger  a  Th1-mediated  cytotoxic  process  in  the 
thyroid gland (32). Why IFN causes Graves’ disease in 
CHC patients is not fully known as Graves’ disease is 
caused by TH-2 mediated humoral immunity which 
has not been reported to be induced by IFN. One 
possible explanation could be the probability that the 
initial phase of Graves’ disease is Th-1 mediated (28). 
Presence  of  antithyroid  antibodies,  female  gender 
and Asian ethnicity being the independent predictors 
of IITD indicate the role of genetic susceptibility. 
Susceptible  genes  have  been  identified,  including 
HLA-DR, CTLA and PTPN 22, thyroglobulin and 
TSH receptor genes (28). Moreover, some evidence 
of the association of IITD with CTLA-4 and CD-40 
gene polymorphism has been found (28).
PEG-IFN  plus  Ribavirin  have  been  reported 
to  be  associated  with  the  occurrence  of  central 
hypothyroidism and hypophysitis in CHC patients, 
which suggests a possible central role (29).
Association of IITD with IFN Treatment Regimens
There are varying results reported in the literature 
regarding  the  association  of  IITD  with  treatment 
regimens in patients with CHC. Patients treated with 
a combination IFN and Ribavirin therapy are reported 
to be more susceptible to IITD than those treated 
with IFN alone (6). In another study, the addition of 
Ribavirin to IFN therapy did not increase the risk of 
thyroid dysfunction compared to IFN alone (4). Carella 
C et al. (10) showed that IFN and Ribavirin combined, 
as compared to IFN alone, did not have a significant 
difference in the occurrence of thyroid autoantibody 
patterns, but the former group of patients had a higher 
risk  of  hypothyroidism.  However,  very  few  studies 
investigated  the  role  of  Ribavirin  in  autoimmune 
diseases,  specially  thyroid  autoimmune  disorders. 
Ribavirin has been used in combination with IFN 
in  CHC  patients  and  never  alone,  so  the  exact 
contribution of Ribavirin itself in the pathogenesis of 
IITD in CHC can not be fully comprehended.
Regarding  those  patients  who  undergo  two 
therapeutic courses, the patients treated for the second 
time with IFN and Ribavirin were protected from the 
development of thyroid autoimmunity and/or thyroid 
dysfunction, (unlike those who were treated with IFN 
alone, as a 1st therapeutic regimen, and were negative 
for  thyroid  autoantibodies)  (6).  The  incidence  of 
thyroid dysfunction is similar for standard IFN and 
PEG-IFN treated patients, so PEG-IFN is not a risk 
factor,  compared  to  standard  IFN  (24). There  are 
varying results in percentage of thyroid dysfunction 
from the first to the second therapeutic schedule of 
IFN. Some studies reveal that in patients undergoing 
two consecutive antiviral treatments, the frequency of 
hypothyroidism increases significantly from the first 
to the second therapeutic schedule, (39) while in others 
there is no significant difference in the frequency of 
thyroid dysfunction during the first and the second 
treatments (5). Further studies and long-term follow-
up of patients undergoing two consecutive antiviral 
courses can help to draw a definite conclusion.
Association  of  IITD  with  Response  to  IFN 
Treatment
The association of the development of IITD with 
long term remission of CHC needs to be investigated 
further.  There  are  varying  results  regarding  the Hepatitis Monthly,  Spring 2010; 10(2): 132-140
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association of IITD and response to treatment. In 
some studies, the development of hypothyroidism 
in  patients  with  thyroid  autoantibodies  who 
undergo treatment with IFN-alpha plus Ribavirin 
is  significantly  associated  with  better  treatment 
response  in  CHC  patients  (39-41). One  study 
revealed that the recovery rate from CHC is better 
in non- autoimmune-type thyroid disease, without 
any autoantibodies in the serum, than in controls 
in  the  same  cohort  (31). Other  studies  show  that 
thyroid dysfunction during the treatment of chronic 
hepatitis  C  with  IFN-alpha  has  no  association 
with efficacy of therapy (42). Whether the immune 
mechanisms  involved  in  the  pathogenesis  of 
thyroid disorders induced by IFN are the same as 
those regulating the therapeutic response in CHC 
patients is not yet clear. The percentage of thyroid 
autoimmunity and thyroid dysfunction in long-term 
responders is not significantly different than that in 
non-responders. Response to therapy is dependent 
on many factors including viral load, virus genotype, 
adherence to therapy, degree of fibrosis in the liver, 
and is not dependent on the absence or presence 
of  IITD.  Therefore,  thyroid  autoimmunity  and 
dysfunction induced by IFN-alpha therapy cannot 
be considered as predictors of treatment response 
or as valid prognostic markers of the progression of 
liver disease (8).
Clinical Features, Diagnosis and Treatment of IITD
Common symptoms of hypothyroidism include 
easy fatigability, anorexia, body aches and depression; 
whereas nervousness, irritability, increased appetite, 
fatigue, insomnia, and weight loss are common in 
overt hyperthyroidism. These symptoms can easily 
be  attributed  to  HCV  infection  itself.  Thyroid 
dysfunction due to non-specific symptoms can easily 
remain  undiagnosed,  if  patients  do  not  undergo 
periodic screening for thyroid dysfunction. The best 
way is to monitor the TSH levels of all patients with 
CHC undergoing treatment before, during and after 
IFN therapy. Periodic serum levels of T3, T4, TSH 
and antithyroid antibodies during IFN therapy and 
in the follow-up period should be closely monitored 
for all patients found to be positive for IITD. Thyroid 
scans should be done if indicated.
The diagnosis of Hashimoto’s thyroiditis is based 
on hypothyroidism with positive thyroid antibodies 
(anti-TPO,  anti-TG).  Destructive  thyroiditis  is 
defined  by  transient  thyrotoxicosis  with  reduced 
radioiodine uptake and negative thyroid antibodies, 
,followed by a hypothyroid phase. The diagnostic 
citeria  for  Graves’  disease  is  a  thyrotoxicosis  with 
either  positive  TRAb  (TSH  receptor  antibodies) 
and/or a diffusely increased thyroid scan uptake (32).
Treatment  for  hyperthyroidism  is  usually 
symptomatic.  Beta  blockers  are  given  for  it. 
Glucocorticoids  are  contraindicated  in  CHC 
patients. In severe forms of Graves’ disease, surgery or 
radioactive ablation may be indicated if the Graves’ 
disease persists even on cessation or completion of 
IFN therapy. Patients who are taking treatment for 
thyroid disease prior to IFN therapy may require 
increased  doses  of  thyroid  medication  during 
antiviral treatment. Doses then have to be decreased 
on completion of IFN therapy.
Patients who develop IFN-induced symptomatic 
hypothyroidism are treated with oral thyroxine and 
usually do not require a decrease in the IFN dose or 
the cessation of antiviral therapy. They may require 
increased doses of thyroxine if they are given a second 
course of IFN (28). Hypothyroidism in most patients 
is  usually  reversible  on  completion  of  antiviral 
treatment.
Outcome of IITD
There are limited studies available on long-term 
follow-up of CHC patients with IITD. Most of the 
data available is about IITD during, at the end of IFN 
treatment and six months after it. . IFN therapy is not 
contraindicated in the presence of autoantibodies , as 
most patients with increased antibody titer recover 
on  completing  therapy.  In  most  patients  IITD  is 
reversible, usually on cessation of antiviral therapy 
(12, 33). All patients with IFN-alpha-induced thyroid 
disorders may not require any treatment for IITD, 
or may be controlled with medication for thyroid 
disease and be able to continue antiviral therapy. In 
some cases, though, reduction in the dose of IFN 
and Ribavirin, and in some others, even cessation 
of antiviral therapy may be necessary, especially in 
thyrotoxicosis patients (3, 40). Which factors determine 
the  reversibility  of  IITD  on  completion  of  IFN 
therapy are yet to be determined by further research 
in this field. The reversibility of IITD in comparison 
to its irreversibility was not found to associated with 
the age of the patient, the HCV genotype, the virus 
type of IFN, the timing of the onset of IITD, the 
cessation of IFN therapy and thyroid hormone levels 
(40). Nevertheless,  the  IFN-alpha-induced  thyroid 
disorder is not always reversible and may require life-
long treatment. Not only should the development 
of autoimmune thyroid disorders during IFN-alpha 
therapy be watched, but also the outcome of the 
thyroid  disease  should  be  followed  up  (40). Long-
term hypothyroidism may persist in a small group Hepatitis Monthly, Spring 2010; 10(2): 132-140
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of  patients  (approximately  2%)  and  may  require 
the lifelong use of thyroid replacement therapy (33, 
42). Thyroid function tests should be checked prior 
to therapy, periodically during therapy, and at least 
once in the six months following therapy. A longer 
follow-up may be needed in positive cases in order 
to confidently establish the complete resolution of 
thyroid disease (14).
The  disease  is  not  reversible  in  all  cases 
of  IFN-alpha-induced  autoimmune  thyroid 
dysfunction. Therefore,  it  is  necessary  that 
autoantibodies and thyroid function be monitored 
during therapy, and the course of thyroid disease be 
observed if autoimmune thyroid disorder develops 
during IFN-alpha and ribavirin treatment (43-46).
Conclusions
IITD is a common complication of IFN therapy 
in  chronic  hepatitis  C  patients.  IFN  can  induce 
different manifestations of thyroid disease, including 
clinical  autoimmune  thyroiditis  (i.e.  Hashimoto’s 
thyroiditis  and  Graves’  disease)  and  non-
autoimmune thyroiditis (i.e. destructive thyroiditis 
and non autoimmune hypothyroidism) in genetically 
susceptible individuals. Hypothyroidism is the most 
common manifestation. Female sex, Asian ethnicity 
and the presence of antithyroid antibodies are the 
independent predictors of IITD. HCV itself plays a 
synergistic role in the pathogenesis of IFN-induced 
thyroid  disease.  Most  patients  can  continue  IFN 
therapy despite the occurrence of IITD, although 
a few patients may require a reduction in dose or 
cessation of IFN therapy due to severe manifestations. 
Chronic hepatitis C patients undergoing IFN therapy 
should  be  regularly  monitored  before  the  onset, 
during and after treatment for the development of 
autoantibodies and thyroid dysfunction.
Future Studies
IITD needs to be explored further. The exact 
pathogenesis of IITD is not yet clear. What is yet 
to  be  determined  is  the  extent  of  IFN-induced 
immunomodulation in patients which can result in 
such diverse clinical manifestations. A few questions 
still  remain  unanswered.  If  genetic  susceptibility 
determines  the  occurrence  of  IITD,  why  does 
IITD  not  occur  in  chronic  hepatitis  B  patients 
who  are  given  higher  doses  of  IFN?  Although 
HCV E2 proteins affect the thyroid cells, what is 
the exact contribution/synergistic effect of CHC 
infection itself in the pathogenesis of IITD? What 
is  the  exact  pathogenesis  of  thyroid  dysfunction 
occurring in some and not in all CHC patients, 
even without IFN therapy? What factors determine 
whether  or  not  a  patient  will  develop  reversible 
thyroid disease? What is the association of IITD 
with treatment response? Long-term follow-up of 
IITD patients is scarce in the literature. Areas of 
future research are long-term follow-up of positive 
cases of IITD to determine reversible/irreversible 
thyroid dysfunction and its relation to sustained 
virological treatment response and relapse. Long-
term follow-up of negative cases of IITD should 
be carried out to determine late development of 
thyroid dysfunction, if any. 
Reported cases of chronic hepatitis C worldwide 
are just the tip of the iceberg. Extensive studies are 
required in this area to understand the pathogenesis 
of  the  disease  and  treatment-related  side  effects. 
Future areas of research are its immunological basis, 
and  the  role  of  genetic,  viral  and  environmental 
factors, in the etiology of IITD. Better knowledge 
of these aspects can lead to a better understanding 
of the pathogenesis of the disease, to improvement 
in  the  management  of  patients  undergoing  IFN 
therapy, to earlier diagnosis of the thyroid side effects 
and to a more appropriate therapeutic approach to 
IITD.
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